(CDAX, Technology, BKHT GR)



Buy EUR **76.00** Price EUR 28.50 **Upside** 166.7 %

Value Indicators:	EUR	Warburg ESG Risk Score:	2.6
SotP:	76.00	ESG Score (MSCI based):	3.0
		Balance Sheet Score:	4.3
		Market Liquidity Score:	0.5
Market Snapshot:	EUR m	Shareholders:	

297.8 Freefloat

Marco Brockhaus

**DWS** Investment

Treasury shares

10.4

488.1

231.1

105.11 th

4.3	German Mittelstand comp	
0.5	Coman Mittolotana comp	ariioo
	Key Figures (WRe):	2024e
7.60 %	Beta:	1.7
1.40 %	Price / Book:	1.3 x
5.90 %	Equity Ratio:	43 %
4.60 %	Net Fin. Debt / EBITDA:	0.6 x
	Net Debt / EBITDA:	0.6 x

Description:

### Strong Bikeleasing development in Q2

(EURm)	Q2 24 A	WRe est	delta	Q2 23 A	YOY	Q1 24 A	QOQ
Revenues	69,4	52,8	31,4%	50,6	37%	39,6	75%
t/o IHSE	7,0	8,8	-20%	9,4	-26%	7,3	-4%
t/o Bikeleasing	62,3	44,0	42%	41,2	51%	32,4	92%
Adj EBITDA	26,4	22,1	19,5%	19,3	37%	11,4	132%
adj. EBITDA margin	38,0%	41,9%		38,1%		28,8%	
t/o IHSE	-0,1	1,4	-107%	2,0	-105%	0,5	-119%
t/o Bikeleasing	28,6	22,5	27%	19,3	48%	12,0	137%

Market cap:

Freefloat MC:

No. of shares (m):

Ø Trad. Vol. (30d):

#### Comment on Figures:

Number of brokered bikes amounts to 54k in Q2 24, yoy growth of 4%.

21

- Number of onboarded companies increased by 5000 in Q2 24, adding around 200k employees to the Bikeleasing platform
- Net income influenced by write-down of EUR 7.9m earn-out receivables from sale of Palas, bringing the reported net income down to EUR 2.0m in Q2 24 and a loss of EUR 5m after minorities.
- IHSE order intake at EUR 11.9m in Q2, leading to a book to bill of 1.7x

There was very strong development in the adj. EBITDA of Bikeleasing in Q2 24, despite relatively low growth in the number of brokered bikes. The development was mainly driven by the acquisition of the dealerships, which added around EUR 1.5m to the improvement, and the adjustment in the leasing factor, which now applies to 90% of the employees connected. The variable leasing factor erases the former adverse effect of the increase in the interest rate. While the increase of nearly 50% in Bikeleasing's EBITDA thus could be viewed as a one-time effect, the adjustment in the variable leasing factor will increase the gross profit per brokered bike sustainably. Hence our model update factors in a comparatively small change in Bikeleasing's adj. EBITDA, even though we have lowered our assumption for the number of brokered bikes by around 10% based on adverse weather conditions and a weaker bike market in Germany overall.

Q2 was somewhat disappointing for IHSE. Revenues were low as projects had longer lead and throughput times, which reduced sales recognition and, in turn, the corresponding gross-profit contribution. While strong order intake should bolster H2 development, we have nevertheless cut our FY 24 adj. EBITDA estimates, leading to a cut of 6% in the group adj. EBITDA forecast.

Management stated that it expects Probonio to make a contribution of around EUR 5m to adj. EBITDA in FY 25e. This would be a payback on investment in less than one year and would represent a ~3% uplift compared to the expected Bikeleasing employee base at the end of FY 24. While we regard this as conservative, we remained prudent regarding the estimated further ramp-up for the time being.

Brockhaus remains a Buy on the back Bikeleasing's increased profit-generation capabilities. PT unchanged at EUR 76.

Changes in E	stimates:					
FY End: 31.12. in EUR m	2024e (old)	+ / -	2025e (old)	+ / -	2026e (old)	+/-
Sales	224.1	2.0 %	284.7	-3.0 %	326.4	-1.1 %
EBITDA adj.	90.4	-6.0 %	114.2	-0.5 %	136.2	0.1 %
Net income	25.5	-18.9 %	37.1	11.0 %	44.9	13.1 %

### Comment on Changes:

- We included Probonio in the Bikeleasing forecast
- For FY 24, we cut the number of brokered bikes by about 10% but raised the revenue estimated for lease return bikes
- We now expect IHSE to show a sales-decline of 10% in FY 24 compared to our previous growth assumption of 12%.
- Write-down of Palas earn-out drives change in net income in FY 24e.




Rel. Performance vs CDAX:	
1 month:	0.3 %
6 months:	26.8 %
Year to date:	5.4 %
Trailing 12 months:	25.8 %

-	
Company events: 14.11.24	Q3

FY End: 31.12. in EUR m	CAGR (23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
III EUK III	(23-206)	2020	2021	2022	2023	20246	20236	20206
Sales (pro forma)	20.0 %	51.6	126.5	145.3	186.7	228.6	276.0	322.8
yoy		-5.0 %	145.3 %	14.9 %	28.5 %	22.5 %	20.7 %	17.0 %
Sales	20.0 %	51.6	60.3	142.7	186.6	228.6	276.0	322.8
Change Sales yoy		211.5 %	16.9 %	136.6 %	30.8 %	22.5 %	20.7 %	17.0 %
EBITDA (pro forma)	29.9 %	12.3	48.2	50.0	62.2	85.0	113.6	136.4
Margin (pro forma)		23.8 %	38.1 %	34.4 %	33.3 %	37.2 %	41.2 %	42.2 %
EBITDA	32.4 %	8.3	0.4	46.7	57.9	80.6	111.6	134.4
Margin		16.2 %	0.7 %	32.7 %	31.0 %	35.3 %	40.4 %	41.6 %
EBIT	43.3 %	-1.0	-9.3	29.3	37.6	57.8	88.9	110.7
Margin		-2.0 %	-15.4 %	20.5 %	20.2 %	25.3 %	32.2 %	34.3 %
Net income	-	-6.8	-15.9	49.0	-3.3	-3.0	23.6	33.2
EPS	-	-0.81	-1.52	4.48	-0.31	-0.28	2.26	3.17
FCFPS		0.57	-0.71	2.90	2.74	0.51	3.96	5.43
FCF / Market cap		1.8 %	-2.9 %	15.4 %	12.5 %	1.8 %	13.9 %	19.1 %
EV / Sales		3.6 x	6.0 x	1.6 x	1.6 x	2.1 x	1.6 x	1.2 x
EV / EBITDA		22.4 x	859.3 x	5.0 x	5.0 x	6.1 x	4.0 x	3.0 x
EV / EBIT		n.a.	n.a.	8.0 x	7.7 x	8.4 x	5.1 x	3.6 x
P/E		n.a.	n.a.	4.2 x	n.a.	n.a.	12.6 x	9.0 x
FCF Potential Yield		2.8 %	-1.1 %	35.5 %	15.6 %	13.1 %	19.3 %	25.7 %
Net Debt		-69.3	110.6	28.1	49.3	46.3	8.0	-44.9
ROCE (NOPAT)		n.a.	n.a.	4.5 %	5.5 %	9.2 %	18.2 %	22.1 %
	Sales of EUR	220-240m a	nd adj. EBITI	DA of EUR 80	0-90m			






### **Company Background**

- Founded in 2017 by CEO Marco Brockhaus and other team members as the successor to three private equity funds.
- In contrast to the limited lifetime of a PE fund, the structure of a holding company precludes forced exits and management influence is increased.
- IPO in 2020
- Portfolio companies are managed by a lean holding with around 10 employees

### **Competitive Quality**

- Brockhaus has an extensive network and over 20 years of expertise in PE transactions to support portfolio companies to grow and expand into new markets
- Focus of investment is scalable B2B business models in high-tech German Mittelstand companies that generate high margins and superior cash returns
- Typically, the companies invested in are not large enough to go to the capital market alone but are champions in their niches
- Brockhaus' investments represent a niche that asset managers have little or no access to.



Sum of the parts



(EURm)	2024	WACC -1%	WACC +1%
Equity value IHSE (DCF)	89	110	73
Share Brockhaus	100%	100%	100%
	89	110	73
Equity value Bikeleasing (DCF)	1.555	1.628	1.490
Share Brockhaus	52%	52%	52%
	813	851	778

-6

6%

-110

Discount factor

Value holding

Sum of the Parts

Less net debt (-cash) holding

Equity value Brockhaus Technologies

FY 24e adj. EBITDA Holding

Number of shares Value per share

792	826	759
1	1	1
791	825	758
<b>791</b>	<b>825</b>	<b>758</b>
10,45	10,45	10,45

-6

5%

-135

-6

7%

-93

IHSE and Bikeleasing valued by separate DCF models

<sup>•</sup> Debt at portfolio company level is included in DCF model. Remaining debt at holding level is subtracted separately.

Holding cost are discounted in a single stage model with same WACC as portfolio companies.

Holding cost are expected to be subject to inflation of 4.5% p.a. subtracted from the discount rate.

Deal generating capabilty of holding is a hidden reserve and not valued currently



Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	1.1 x	1.1 x	0.8 x	0.9 x	1.3 x	1.2 x	1.1 x
Book value per share ex intangibles	6.81	-16.15	-7.70	-9.41	-8.49	-5.18	-0.90
EV / Sales	3.6 x	6.0 x	1.6 x	1.6 x	2.1 x	1.6 x	1.2 x
EV / EBITDA	22.4 x	859.3 x	5.0 x	5.0 x	6.1 x	4.0 x	3.0 x
EV / EBIT	n.a.	n.a.	8.0 x	7.7 x	8.4 x	5.1 x	3.6 x
EV / EBIT adj.*	17.6 x	18.3 x	5.0 x	5.0 x	6.1 x	4.2 x	3.0 x
P/FCF	54.1 x	n.a.	6.5 x	8.0 x	56.2 x	7.2 x	5.2 x
P/E	n.a.	n.a.	4.2 x	n.a.	n.a.	12.6 x	9.0 x
P / E adj.*	57.9 x	52.2 x	25.9 x	19.5 x	14.4 x	7.2 x	5.9 x
Dividend Yield	n.a.	n.a.	n.a.	1.0 %	1.0 %	1.3 %	1.7 %
FCF Potential Yield (on market EV)	2.8 %	-1.1 %	35.5 %	15.6 %	13.1 %	19.3 %	25.7 %
*Adjustments made for: -							


Company Specific Items							
	2020	2021	2022	2023	2024e	2025e	2026e
Sales (pro forma)	51.6	126.5	145.3	186.7	228.6	276.0	322.8
yoy	-5.0 %	145.3 %	14.9 %	28.5 %	22.5 %	20.7 %	17.0 %
EBITDA (pro forma)	12.3	48.2	50.0	62.2	85.0	113.6	136.4
Margin (pro forma)	23.8 %	38.1 %	34.4 %	33.3 %	37.2 %	41.2 %	42.2 %



Consolidated profit & loss							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026
Sales	51.6	60.3	142.7	186.6	228.6	276.0	322.8
Change Sales yoy	211.5 %	16.9 %	136.6 %	30.8 %	22.5 %	20.7 %	17.0 %
Increase / decrease in inventory	-0.1	-0.2	-0.2	0.1	0.0	0.0	0.0
Own work capitalised	0.9	1.4	1.0	1.0	0.0	0.0	0.0
Total Sales	52.3	61.5	143.5	187.7	228.6	276.0	322.8
Material expenses	13.8	14.2	51.7	69.3	80.0	96.6	113.0
Gross profit	38.6	47.3	91.7	118.4	148.6	179.4	209.8
Gross profit margin	74.7 %	78.4 %	64.3 %	63.4 %	65.0 %	65.0 %	65.0 %
Personnel expenses	19.5	21.8	26.6	33.1	43.4	52.4	61.3
Other operating income	1.5	2.0	1.5	4.1	2.3	2.8	3.2
Other operating expenses	12.0	26.9	19.5	31.5	26.8	18.1	17.4
Unfrequent items	-0.1	-0.2	-0.3	0.0	0.0	0.0	0.0
EBITDA	8.3	0.4	46.7	57.9	80.6	111.6	134.4
Margin	16.2 %	0.7 %	32.7 %	31.0 %	35.3 %	40.4 %	41.6 %
Depreciation of fixed assets	1.7	2.1	3.2	4.6	4.1	5.0	5.8
EBITA	6.7	-1.7	43.5	53.3	76.5	106.6	128.5
Amortisation of intangible assets	7.7	7.6	14.2	15.7	18.7	17.8	17.8
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	-1.0	-9.3	29.3	37.6	57.8	88.9	110.7
Margin	-2.0 %	-15.4 %	20.5 %	20.2 %	25.3 %	32.2 %	34.3 %
EBIT adj.	10.6	19.7	46.8	57.7	80.7	108.4	130.2
Interest income	0.1	0.0	4.8	0.5	1.2	1.2	1.2
Interest expenses	3.9	6.2	14.7	19.8	15.8	14.6	14.3
Other financial income (loss)	0.0	0.0	0.0	0.0	4.9	-3.0	-3.0
EBT	-4.8	-15.4	19.3	18.4	32.3	72.5	94.7
Margin	-9.4 %	-25.5 %	13.5 %	9.9 %	14.1 %	26.3 %	29.3 %
Total taxes	1.9	3.4	8.9	9.1	14.5	21.0	27.5
Net income from continuing operations	-6.8	-18.8	10.5	9.3	17.8	51.5	67.2
Income from discontinued operations (net of tax)	0.0	0.0	48.0	0.0	0.0	0.0	0.0
Net income before minorities	-6.8	-18.8	58.5	9.3	17.8	51.5	67.2
Minority interest	0.0	-2.9	9.4	12.7	20.7	27.9	34.1
Net income	-6.8	-15.9	49.0	-3.3	-3.0	23.6	33.2
Margin	-13.1 %	-26.3 %	34.3 %	-1.8 %	-1.3 %	8.5 %	10.3 %
Number of shares, average	8.3	10.4	10.9	10.9	10.4	10.4	10.4
EPS	-0.81	-1.52	4.48	-0.31	-0.28	2.26	3.17
EPS adj.	0.53	0.46	0.73	1.13	1.98	3.94	4.86
*Adjustments made for:							

Guidance: Sales of EUR 220-240m and adj. EBITDA of EUR 80-90m


Financial Ratios									
	2020	2021	2022	2023	2024e	2025e	2026e		
Total Operating Costs / Sales	85.0 %	101.0 %	67.6 %	69.6 %	64.7 %	59.6 %	58.4 %		
Operating Leverage	-0.3 x	46.5 x	n.a.	0.9 x	2.4 x	2.6 x	1.4 x		
EBITDA / Interest expenses	2.1 x	0.1 x	3.2 x	2.9 x	5.1 x	7.7 x	9.4 x		
Tax rate (EBT)	-39.7 %	-22.0 %	45.8 %	49.4 %	45.0 %	29.0 %	29.0 %		
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	25.9 %	16.8 %	7.5 %	7.5 %		
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		





Consolidated balance sheet							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026
Assets							
Goodwill and other intangible assets	152.7	398.9	356.9	356.6	325.5	307.7	289.9
thereof other intangible assets	53.7	147.7	133.5	119.3	100.6	82.8	65.0
thereof Goodwill	91.4	243.6	221.9	222.8	222.8	222.8	222.8
Property, plant and equipment	11.7	16.2	7.6	12.9	11.4	11.7	12.4
Financial assets	0.0	0.0	0.0	0.0	-7.9	-7.9	-7.9
Other long-term assets	0.6	82.7	131.4	139.5	193.6	244.0	254.0
Fixed assets	165.0	497.7	496.0	509.0	522.6	555.5	548.4
Inventories	9.7	12.6	10.9	17.7	17.6	21.2	24.8
Accounts receivable	7.2	20.2	29.4	36.2	69.0	83.3	97.5
Liquid assets	123.5	30.3	70.8	53.7	31.7	45.0	72.9
Other short-term assets	0.9	53.7	48.4	49.6	53.4	46.0	40.1
Current assets	141.4	116.8	159.5	157.2	171.7	195.5	235.3
Total Assets	306.4	614.5	655.5	666.2	694.3	751.1	783.7
Liabilities and shareholders' equity							
Subscribed capital	10.4	10.4	10.9	10.9	10.9	10.9	10.9
Capital reserve	227.7	227.7	240.1	240.1	240.1	240.1	240.1
Retained earnings	0.0	0.0	0.0	18.3	13.0	32.2	61.5
Other equity components	-14.6	-16.0	21.6	-11.0	-27.2	-29.7	-32.0
Shareholders' equity	223.4	222.0	272.7	258.3	236.8	253.6	280.6
Minority interest	0.0	32.9	42.6	39.5	60.3	89.5	123.6
Total equity	223.4	254.9	315.3	297.8	297.1	343.1	404.1
Provisions	2.2	4.9	0.2	0.2	0.2	0.2	0.2
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	54.3	140.9	98.9	103.0	78.0	53.0	28.0
Short-term financial liabilities	6.1	17.0	5.3	15.9	15.9	15.9	15.9
Accounts payable	2.5	12.7	15.5	15.2	28.9	34.9	40.8
Other liabilities	24.0	201.0	225.7	250.0	290.1	319.9	310.6
Liabilities	83.0	359.6	340.2	368.3	397.2	408.0	379.6
Total liabilities and shareholders' equity	306.4	614.5	655.5	666.2	694.3	751.1	783.7


Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	2.0 x	1.7 x	4.4 x	3.6 x	3.3 x	3.4 x	3.4 x
Capital Employed Turnover	0.3 x	0.2 x	0.4 x	0.5 x	0.7 x	0.8 x	0.9 x
ROA	-4.1 %	-3.2 %	9.9 %	-0.7 %	-0.6 %	4.2 %	6.0 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	4.5 %	5.5 %	9.2 %	18.2 %	22.1 %
ROE	-3.9 %	-7.1 %	19.8 %	-1.3 %	-1.2 %	9.6 %	12.4 %
Adj. ROE	2.6 %	2.1 %	3.3 %	4.6 %	8.4 %	16.8 %	19.0 %
Balance sheet quality							
Net Debt	-69.3	110.6	28.1	49.3	46.3	8.0	-44.9
Net Financial Debt	-69.3	110.6	28.1	49.3	46.3	8.0	-44.9
Net Gearing	-31.0 %	43.4 %	8.9 %	16.6 %	15.6 %	2.3 %	-11.1 %
Net Fin. Debt / EBITDA	n.a.	n.a.	60.1 %	85.2 %	57.5 %	7.2 %	n.a.
Book Value / Share	21.5	20.3	24.9	24.7	22.7	24.3	26.9
Book value per share ex intangibles	6.8	-16.2	-7.7	-9.4	-8.5	-5.2	-0.9





Consolidated cash flow statement							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026
Net income	-6.8	-18.8	58.5	9.3	17.8	51.5	67.2
Depreciation of fixed assets	9.4	9.7	5.9	4.6	4.1	5.0	5.8
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	7.7	7.6	14.2	15.7	18.7	17.8	17.8
Increase/decrease in long-term provisions	0.0	-0.1	0.0	0.0	0.0	0.0	0.0
Other non-cash income and expenses	-3.4	-9.9	-31.9	20.3	-15.0	-17.0	-17.0
Cash Flow before NWC change	7.0	-11.5	46.6	49.9	25.6	57.2	73.8
Increase / decrease in inventory	-1.1	-2.3	-16.1	-6.8	0.1	-3.6	-3.6
Increase / decrease in accounts receivable	0.0	0.0	0.0	-6.8	-32.8	-14.3	-14.2
Increase / decrease in accounts payable	-0.2	7.6	4.6	-0.3	13.7	6.0	5.9
Increase / decrease in other working capital positions	0.0	0.0	-0.2	-1.2	1.3	1.3	1.3
Increase / decrease in working capital (total)	-1.3	5.3	-11.7	-15.1	-17.6	-10.6	-10.6
Net cash provided by operating activities [1]	5.7	-6.2	34.9	34.8	8.0	46.6	63.2
Investments in intangible assets	-0.1	0.0	0.0	0.0	0.0	0.0	0.0
Investments in property, plant and equipment	-1.0	-1.2	-1.3	-2.3	-2.7	-5.3	-6.5
Payments for acquisitions	-0.1	-142.1	0.0	-15.2	0.0	0.0	0.0
Financial investments	-0.4	-0.8	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.1	56.2	10.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-1.4	-144.0	53.0	-9.9	-2.7	-5.3	-6.5
Change in financial liabilities	0.0	58.0	-42.4	-15.8	-25.0	-25.0	-25.0
Dividends paid	0.0	0.0	0.0	0.0	-2.3	-3.0	-3.9
Purchase of own shares	0.0	0.0	0.0	-11.0	0.0	0.0	0.0
Capital measures	112.7	0.0	0.0	0.0	0.0	0.0	0.0
Other	-10.4	-2.4	-4.3	-15.8	0.0	0.0	0.0
Net cash provided by financing activities [3]	102.3	55.7	-46.7	-42.6	-27.3	-28.0	-28.9
Change in liquid funds [1]+[2]+[3]	106.6	-94.5	41.2	-17.7	-22.0	13.4	27.9
Effects of exchange-rate changes on cash	0.2	0.3	0.2	-0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	124.0	29.3	71.8	53.0	31.7	45.0	72.9

Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	4.7	-7.4	31.8	30.0	5.3	41.3	56.8
Free Cash Flow / Sales	9.2 %	-12.2 %	22.3 %	16.1 %	2.3 %	15.0 %	17.6 %
Free Cash Flow Potential	5.3	-3.8	83.5	45.2	64.1	86.6	102.0
Free Cash Flow / Net Profit	<i>-</i> 70.0 %	46.5 %	64.8 %	-897.5 %	-178.3 %	175.4 %	171.2 %
Interest Received / Avg. Cash	0.1 %	0.1 %	9.5 %	0.8 %	2.8 %	3.1 %	2.0 %
Interest Paid / Avg. Debt	6.7 %	6.3 %	12.3 %	19.6 %	17.4 %	22.2 %	35.2 %
Management of Funds							
Investment ratio	2.0 %	1.9 %	0.9 %	1.2 %	1.2 %	1.9 %	2.0 %
Maint. Capex / Sales	2.1 %	1.5 %	1.7 %	1.9 %	0.9 %	1.4 %	1.5 %
Capex / Dep	11.2 %	12.1 %	7.2 %	11.4 %	11.7 %	23.2 %	27.4 %
Avg. Working Capital / Sales	27.0 %	28.5 %	15.7 %	17.0 %	21.1 %	23.1 %	23.4 %
Trade Debtors / Trade Creditors	284.5 %	158.4 %	190.1 %	238.9 %	238.8 %	238.7 %	239.0 %
Inventory Turnover	1.4 x	1.1 x	4.7 x	3.9 x	4.5 x	4.6 x	4.6 x
Receivables collection period (days)	51	122	75	71	110	110	110
Payables payment period (days)	67	326	109	80	132	132	132
Cash conversion cycle (Days)	241	118	43	84	59	58	59



Source: Warburg Research Source: Warburg Research



#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer/htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5**% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Brockhaus Technologies	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer en/DE000A2GSU42.htm



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	141	70
Hold	43	21
Sell	11	5
Rating suspended	6	3
Total	201	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	41	75
Hold	10	18
Sell	2	4
Rating suspended	2	4
Total	55	100

#### PRICE AND RATING HISTORY BROCKHAUS TECHNOLOGIES AS OF 19.08.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	<b>Hannes Müller</b> Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270	Andreas Pläsier Banks, Financial Services	+49 40 309537-246
Stefan Augustin	hrueschmeier@warburg-research.com +49 40 309537-168	Malte Schaumann	aplaesier@warburg-research.com +49 40 309537-170
Cap. Goods, Engineering	saugustin@warburg-research.com	Technology	mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs	+49 40 309537-175	Simon Stippig	+49 40 309537-265
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com
<b>Dr. Christian Ehmann</b> BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290
Software, IT	fellmann@warburg-research.com	Technology	rvanderhorst@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185		
Fabio Hölscher	mfuhrberg@warburg-research.com +49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com		
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer	+49 40 309537-257		
Retail, Consumer Goods	tkleibauer@warburg-research.com		
INSTITUTIONAL EQUI	TY SALES		
Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400	Sascha Propp France	+49 40 3282-2656
Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	France	spropp@mmwarburg.com
United Kingdom	tbeckmann@mmwarburg.com		
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com		
Matthias Fritsch	+49 40 3282-2696	Antonia Möller	+49 69 5050-7417
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	amoeller@mmwarburg.com
Rudolf Alexander Michaelis Germany	+49 40 3282-2649 rmichaelis@mmwarburg.com	Charlotte Wernicke Roadshow/Marketing	+49 40 3282-2669 cwernicke@mmwarburg.com
Roman Alexander Niklas	+49 69 5050-7412	Juliane Niemann	+49 40 3282-2694
Switzerland, Poland	rniklas@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOF	RING
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading  Rico Müller	omerckel@mmwarburg.com +49 40 3282-2685	Designated Sponsoring Sebastian Schulz	mmagiera@mmwarburg.com +49 40 3282-2631
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast Sales Trading	+49 40 3282-2701 bquast@mmwarburg.com	Jörg Treptow  Designated Sponsoring	+49 40 3282-2658 itreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research  Our research can be for	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
		1050	
Warburg Research Bloomberg	research.mmwarburg.com/en/index.html RESP MMWA GO	LSEG Capital IQ	www.lseg.com www.capitaliq.com
FactSet	www.factset.com	Οαριιαι IQ	www.capitanq.com
For access please contact			
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com